Last update June 24, 2020


Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Monoclonal antibody fragment that binds to platelet receptors inhibiting platelet aggregation. Used to treat angioplasty and unstable angina.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data: very high molecular weight, high percentage of platelet binding (Harder 1999) and short half-life, make it very unlikely it will pass into breast milk in significant amounts.

Due to its protein nature, it deteriorates in the gastrointestinal tract, not being absorbed. This low oral bioavailability would make it difficult for it to pass to the infant’s plasma ingesting breast milk, except in preterm infants and in the immediate neonatal period when there may be increased intestinal permeability.


  • Aspirin (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Heparin ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Abciximab in other languages or writings:


Abciximab belongs to this group or family:


Main tradenames from several countries containing Abciximab in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 47.456 daltons
T1/2 0,2 - 0,5 hours


  1. Abciximab Ficha técnica 2013 Full text (in our servers)
  2. Abciximab Data sheet 2013 Full text (in our servers)
  3. Harder S, Kirchmaier CM, Krzywanek HJ, Westrup D, Bae JW, Breddin HK. Pharmacokinetics and pharmacodynamic effects of a new antibody glycoprotein IIb/IIIa inhibitor (YM337) in healthy subjects. Circulation. 1999 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM